Did A Product Swap Fuel JNJ Stock’s 54% Surge?

The signs were not in the headline growth rate but in which two products were trading places.

Johnson & Johnson (JNJ) stock returned 54% between late August 2025 and late August 2026, against 20.5% for the S&P 500. Nothing in the headline financials called it. What did was a swap the company had been describing product by product for seven months before the run began: one immunology franchise going away, and a named replacement aimed at the same patients.

The Replacement Was Named Before It Showed Up

The company’s fourth-quarter 2024 results reflected a transition period as management absorbed expected loss of exclusivity (LOE), positioning next-generation immunology assets to offset biosimilar erosion. STELARA fell 13.6% ahead of the January 2025 US biosimilar entry. In the same report management named one of the launches meant to cover the hole, TREMFYA in inflammatory bowel disease, at a point when TREMFYA was itself growing only 5.6%.

By Mid-2025 The Two Lines Had Separated

Six months on, the July 2025 report put STELARA down 43.2% and TREMFYA up 30.1% on share gains and uptake in its newer ulcerative colitis and Crohn’s disease indications. What made that a signal rather than a coincidence is where the lost volume sat: management said about 70% of STELARA’s prescriptions were in inflammatory bowel disease, so the replacement was aimed at the exact indication being lost. Excluding STELARA, the other 90% of Innovative Medicine grew 15.5%.

Everything Louder Pointed Somewhere Else

None of this reached the headline growth rate. Trailing-twelve-month revenue through fiscal Q2 2025 was $90.63 billion, up 4.7%, close to the 4.0% average of the three years through that report. In the legal sphere, a notable development that July was a $42.6 million Boston talc verdict, billed as a Massachusetts mesothelioma record. And by mid-August 2025 implied volatility had eased to the 9th percentile of its trailing one-year range, from the 43rd a month earlier, so the options market was braced for an unusually small move in either direction.

What Landed In July 2026

July 2026 brought a cluster of headline-grabbing catalysts in quick succession: the FDA authorized the OTTAVA surgical robot on July 22, the company proposed a comprehensive resolution for remaining ovarian talc litigation on July 27, and the Firefly Bio acquisition closed two days later.

Yet while regulatory clearances, pipeline deals, and legal de-risking cleared key overhangs, it was the commercial swap that provided the structural floor under the financials. That handoff finished the job in the second-quarter 2026 report: TREMFYA surged 71% to its first $2 billion quarter, offsetting a 55.7% decline in STELARA, and lifted the operational sales outlook to a $100.6 billion midpoint. Revenue growth that holds up through the loss of a product as large as STELARA is exactly the durability the Trefis High Quality Portfolio looks for in its holdings.

Legible In Advance, But Only At The Product Level

So were the signs actionable? Partly. Each was dated and public, but each sat in product-level disclosure rather than in the aggregate line most investors watch. Nor was 54% the sector’s top mark—peers unburdened by active biosimilar erosion like Merck (MRK) and Eli Lilly (LLY) ran harder at 81.8% and 60.8% on unencumbered volume growth, while Pfizer (PFE) managed 20.3%—underscoring that JNJ’s run was neither a rising sector tide nor market-leading momentum, but the specific re-rating of a business successfully neutralizing an immediate revenue cliff. Talc litigation remains an active factor, as demonstrated by an August 24, 2026 Louisiana jury verdict awarding $10 million. The repeatable habit is narrow: when a company names the product meant to replace one it is losing, track the replacement’s growth and whether it lifts the outlook, which is what the Guidance Momentum screen ranks.

Even A Handoff This Well-Signposted Is Still One Company

Reading one company’s disclosure this closely is a real skill, and it still leaves the outcome resting on one management team. A rules-based portfolio turns that reading into a repeatable process. That portfolio has a track record of outpacing the three major indices – the S&P 500, S&P Mid-cap, and Russell 2000.